Cover Image
市場調查報告書

NeoPharm Co., Ltd. - 產品平台分析

Neopharm Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 311245
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
NeoPharm Co., Ltd. - 產品平台分析 Neopharm Ltd. - Product Pipeline Review - 2015
出版日期: 2015年09月09日 內容資訊: 英文 26 Pages
簡介

NeoPharm Co Ltd. 身為護膚產品廠商,正製造、銷售抗老化效果的藥用化妝品,及潔顏慕絲,洗髮精,肥皂,防曬油,具有止痛效果的乳霜,以及特異反應性和乾燥,敏感性皮膚用的各種產品。該公司同時也在進行癌症和皮膚炎,氣喘,異位性皮膚炎,第二型糖尿病等治療藥的新開發,其產品與技術普及全球。

本報告提供NeoPharm Co., Ltd.的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

NeoPharm Co., Ltd.的基本資料

NeoPharm Co., Ltd.概要

  • 主要資訊
  • 企業資料

NeoPharm Co., Ltd.:R&D概要

  • 主要的治療範圍

NeoPharm Co., Ltd.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

NeoPharm Co., Ltd.:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

NeoPharm Co., Ltd.:藥物簡介

  • NPB-112
  • NPB-3
  • NPS-1
  • NPS-1034
  • Protein for Allergies
  • Small Molecule for Allergic Asthma
  • NPB-2
  • NPS-2
  • NPS-3
  • NPS-4

NeoPharm Co., Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

NeoPharm Co., Ltd.:企業發表

NeoPharm Co., Ltd.:總公司和子公司的所在地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07570CDB

Summary

Global Markets Direct's, 'Neopharm Ltd. - Product Pipeline Review - 2015', provides an overview of the Neopharm Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Neopharm Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Neopharm Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Neopharm Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Neopharm Ltd.'s pipeline products

Reasons to buy

  • Evaluate Neopharm Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Neopharm Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Neopharm Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Neopharm Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neopharm Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Neopharm Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Neopharm Ltd. Snapshot
    • Neopharm Ltd. Overview
    • Key Information
    • Key Facts
  • Neopharm Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Neopharm Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Neopharm Ltd. - Pipeline Products Glance
    • Neopharm Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Neopharm Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
  • Neopharm Ltd. - Drug Profiles
    • anti-thymocyte globulin (rabbit)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ertumaxomab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FBTA-05
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neopharm Ltd. - Pipeline Analysis
    • Neopharm Ltd. - Pipeline Products by Target
    • Neopharm Ltd. - Pipeline Products by Route of Administration
    • Neopharm Ltd. - Pipeline Products by Molecule Type
    • Neopharm Ltd. - Pipeline Products by Mechanism of Action
  • Neopharm Ltd. - Recent Pipeline Updates
  • Neopharm Ltd. - Dormant Projects
  • Neopharm Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Neopharm Ltd., Key Information
  • Neopharm Ltd., Key Facts
  • Neopharm Ltd. - Pipeline by Indication, 2015
  • Neopharm Ltd. - Pipeline by Stage of Development, 2015
  • Neopharm Ltd. - Monotherapy Products in Pipeline, 2015
  • Neopharm Ltd. - Partnered Products in Pipeline, 2015
  • Neopharm Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Neopharm Ltd. - Phase III, 2015
  • Neopharm Ltd. - Phase I, 2015
  • Neopharm Ltd. - Pipeline by Target, 2015
  • Neopharm Ltd. - Pipeline by Route of Administration, 2015
  • Neopharm Ltd. - Pipeline by Molecule Type, 2015
  • Neopharm Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Neopharm Ltd. - Recent Pipeline Updates, 2015
  • Neopharm Ltd. - Dormant Developmental Projects,2015

List of Figures

  • Neopharm Ltd. - Pipeline by Top 10 Indication, 2015
  • Neopharm Ltd. - Pipeline by Stage of Development, 2015
  • Neopharm Ltd. - Monotherapy Products in Pipeline, 2015
  • Neopharm Ltd. - Pipeline by Top 10 Target, 2015
  • Neopharm Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Neopharm Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Neopharm Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top